FMP
NASDAQ
43.33 USD
1.54 (3.55%)
Dr. David P. Meeker M.D.
Healthcare
Biotechnology
https://www.rhythmtx.com
NASDAQ
Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of rare genetic diseases of obesity. The company's lead product candidate is IMCIVREE, a potent melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is also developing setmelanotide, which is in Phase II clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesit...
0001649904
US76243J1051
76243J105
222 Berkeley Street
857 264 4280
US
226
Oct 9, 2017
0001649904
NASDAQ
Biotechnology
Healthcare
76243J105
US76243J1051
US
43.33
1.9
669.97k
2.61B
-
15.5-52.57
-26.64
-
-
-
-
-13.54
-
https://www.rhythmtx.com
We are unable to load the chart at this time.
We are unable to load the chart at this time.
We are unable to load the chart at this time.
We are unable to load this data!
Financial Information
Financial Summary Real-Time Price
Financial Statements
Financial Quarter Statements
Ratios Analysis
Dupont Analysis
Free Cashflow
Operating Data
Balance Sheet Data
Financial Modelling
Discounted Cashflow Model
Discounted Cashflow Model Levered
Free Cashflow Build-Up
Terminal Value
Intrinsic Value
Weighted Average Cost of Capital
Market Information
Stock Value
It looks like there's no news available.